Compare JOF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JOF | STTK |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.1M | 275.9M |
| IPO Year | N/A | 2020 |
| Metric | JOF | STTK |
|---|---|---|
| Price | $11.01 | $6.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 101.7K | ★ 691.5K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.43 | $0.69 |
| 52 Week High | $12.76 | $6.81 |
| Indicator | JOF | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 67.18 |
| Support Level | $10.16 | $5.75 |
| Resistance Level | $11.00 | $6.81 |
| Average True Range (ATR) | 0.18 | 0.37 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 74.68 | 70.79 |
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.